HIV

J&J Ends Mosaico HIV Vaccine Trial on poor Results

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board for its latest Phase 3 trial found that the shot was no better than a placebo.

News

GSK Raises Bet on AIDS Drug with New Shionogi Deal

Top-Feature

INOSIM GmbH

Predictive Simulation in Pharma Production

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Event Sponsorship: Next Generation Batteries and Hydrogen

Free Virtual Event

CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Bayer AG

HIV